唑来膦酸治疗维吾尔族绝经后妇女骨质疏松症患者的临床观察

目的探讨注射用唑来膦酸治疗新疆维吾尔族绝经后妇女骨质疏松患者的临床疗效。方法选取2011年6—11月新疆维吾尔自治区人民医院收治的维吾尔族绝经后妇女骨质疏松症患者42例，未曾行任何抗骨质疏松症治疗，同时排除其他骨代谢性疾病或药物影响，随机分为治疗组和对照组，治疗组21例，平均年龄60．4岁，给予唑来膦酸5mg，静脉滴注30min，同时口服钙尔奇600mg／d及阿尔法D3O．25μg／d；对照组21例，平均年龄61．2岁，给予口服钙尔奇600mg／d及阿尔法D3O．25μg／d，治疗时间12个月，采用双能x线骨密度仪（DEXA）测定两组治疗前及治疗12个月后的腰椎1～4、股骨颈、Ward’S三角区骨密度值。结果治疗组2例患者失访。治疗组患者治疗12个月后腰椎1～4、股骨颈、Ward’S三角区骨密度值均高于治疗前，且均显著高于对照组（P〈O．05）。治疗组4例患者在注射唑来膦酸后出现发热、头痛及流感样症状，给予非甾体抗炎药（NSAIDs）对症治疗后均在3d内缓解，未见肾损害、消化道不适、下颌骨坏死等不良反应。结论唑来膦酸注射液（5mg）可明显提高维吾尔族绝经后女性骨质疏松症患者的骨密度，且不良反应可耐受，在绝经后妇女骨质疏松症患者中值得推广应用。

Clinical observation of azole phosphonic acid treatment Xinjiang Uyghur patients with postmenopausal osteoporosis

Objective To investigate the clinical curative effect of Azole phosphonic acid treatment on Xin- jiang Uyghur patients with postmenopausal osteoporosis. Methods 42 Uyghur patients with postmenopa- usal osteoporosis with no anti-osteoporosis treatment or other bone metabolic disease or drug e{{ects were selected from June to November 2011 in Xinjiang Uyghur Autonomous Regional People＇s Hospital, and they were randomly divided into treatment group and control group. There were 21 cases in treatment group, with an average＂ age of 60.4, and they were treated with 5 mg phosphonic acid in 30 min intravenous drip and oral calcium, 600 mg/d and alpha D3 0.25 ~g/d~ 21 cases were in control group, with an average age of 61.2, and oral calcium, 600 mg/d and alpha D3 0.25 gg/d. Both groups were treated for 12 months.Dual-energy X-ray absorptiometry （DEXA） （DEXA） was adopted to determine the mineral density values of 1--4 lumbar spine, femoral neck, Wardts triangle bone in two groups pre-and post treatment. Results 2 cases in the treatment group were lost to follow-up, and the mineral density values of the treatment group patients in 1--4 lumbar spine, femoral neck, Ward＇s triangle bone were higher than their pre-treat- ment, and were significantly higher than those of control group （P （0.05）. 4 patients in treatment group had influenza-like symptoms of fever, headache after the injection of azole phosphonic acid but relieved with non-steroidal anti-inflammatory drugs （NSAIDs） within 3 days, without kidney damage, gastrointes- tinal discomfort and osteonecrosis. Conclusion Azole phosphonic acid injection （5 mg） can obviously im- prove the bone mineral density in Uyghur postmenopausal women with osteoporosis, and adverse reactions can be tolerated. Therefore, it＇s worthwhile to popularize and apply the treatment of Azole phosphonic acid injection in patients with postmenopausal osteoporosis.